VRS-317: Phase III started

Versartis began the open-label, international Phase III VELOCITY trial to compare 3.5 mg/kg subcutaneous VRS-317 semi-monthly vs. subcutaneous rhGH once daily for 1 year in up to 136 treatment-naïve p...